ChinaBio Today -- Hemispherx Biopharma of the US has struck a deal with China CRO Fountain Medical Development under which Fountain will file to gain SFDA approval for a clinical trial of Ampligen® in China. Ampligen is an antiviral that seeks to amplify an individual’s immune response. In the trial, the drug will be tested as a treatment for patients hospitalized with the flu, many of whom have underlying respiratory diseases. More details...
